Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label long-term lanadelumab in non-histaminergic normal C1-INH angioedema
jRCT2051220001Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of lanadelumab in angioedema, sponsored by Takeda. Primary endpoints: Number of participants with treatment-emergent adverse events (TEAEs), AESI, and SAEs during treatment period and Number of participants with treatment-emergent adverse events (TEAEs), AESI, and SAEs during follow-up. Started Feb 2021; status: completed.
02
Drugs
lanadelumab
03
Conditions
angioedema
Beyond the preview
Go deeper on jRCT2051220001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220001.